Background-The pathology and clinical course of patients with CD5+ chronic B-cell lymphoproliferative disorders, excluding those that present with typical chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or mantle cell lymphoma, (i.e. CD5+B-CLPD) are poorly defined.
Introduction
Chronic B-cell lymphoproliferative disorders (B-CLPD) are a biologically heterogeneous group of malignant diseases characterized by accumulation of mature B lymphocytes in the bone marrow (BM), peripheral blood, and lymphoid tissues. B-CLPD is now most often diagnosed by flow cytometric immunophenotyping that identifies a clonal light-chain restricted population expressing B-cell markers in the blood or BM (1) . In most of these patients further characterization of the clonal population is diagnostic for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) or the leukemic phase of a known lymphoma (2) (3) (4) . However, in a minority of patients, no specific pathological diagnosis can be made.
Patients with these non-specific B-CLPDs can be further subclassified according to the expression of CD5 (3) . Those with a B-CLPD that does not express CD5 will usually be found to have the leukemic phase of a well defined lymphoma such as marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular cell lymphoma (FCL), or hairy cell leukemia (HCL) (5) . However, determining the diagnosis of the underlying lymphoid malignancy in those patients with B-CLPD that expresses CD5 but does not have the characteristic immunophenotypic and genetic features of CLL or mantle cell lymphoma (MCL) (i.e. CD5+B-CLPD), can be more difficult (6) . We hypothesized that this population of patients could include some with a novel disease entity (7) . To test this hypothesis we examined the clinical and pathological diagnosis and characteristics of 229 patients with CD5+B-CLPD.
Methods

Patients
This study was conducted at Mayo Clinic Rochester (MCR) with the approval of the Institutional Review Board. All patients with CD5+B-CLPD who were seen at least once in the Division of Hematology at MCR between January 1, 1996 and May 1, 2008 were evaluated for inclusion in the study. This period was selected for study because of the introduction of standardized flow cytometry methods and diagnostic criteria prior to 1995 which were then used with only minor modification throughout the study. Patients were identified using the MCR Pathology database, the CLL Database, and the Institutional Database of diagnoses based on International Classification of Diseases (ICD)-9 codes (204. 1, 204.11, 204.12, 204.9, 238 .79) appropriate for CLL (including small lymphocytic lymphoma) and B-CLPD.
Patients were included in the analysis if their blood or BM contained a monoclonal CD5 positive B cell population identified by flow cytometry which did not have the characteristic immunophenotype of CLL using imunophenotypic criteria as previously described(3). MCL was excluded by testing for either t (11;14) by interphase fluorescent in situ hybridization (FISH) or immunohistochemical staining for expression of cyclin D1 characteristic of MCL (3, 8) . Clinical information on age, gender, clinical presentation (B symptoms, autoimmune complications, and other relevant symptoms), physical examination (presence of peripheral lymphadenopathy, splenomegaly, hepatomegaly, and extranodal involvement), treatment history, disease related complications, and the cause of death were abstracted from clinical records on all patients. Laboratory data collected included total white blood cell count, absolute lymphocyte count (ALC), hemoglobin level, platelet count, and the results of serum monoclonal protein evaluations. Results of flow cytometry immunophenotyping analysis and all available BM and tissue biopsies were blindly reviewed by two expert hematopathologists (C.H. and D.J.). CLL was diagnosed in histological specimens by characteristic morphologic (effacement of architecture by monotonous proliferation of small lymphocytes with clumped chromatin, no prominent nucleoli, and scant amount of cytoplasm, presence of proliferation centers composed of larger prolymphocytes and paraimmunoblasts) and immunophenotypic (coexpression of CD5 and CD23, and cyclin D1 negative) features (9, 10) . Prognostic data collected included CD38 expression, FISH, and conventional cytogenetic testing results when available. FISH data were included if the test was done pre-treatment and within two years of the diagnosis of the CLPD, and laboratory values were included if done pre-treatment and within six months of the diagnosis of the CLPD. FISH testing and CD38 analysis were not routine laboratory procedures for CLPD during the entirety of the study period, and therefore, the results were not available for all patients. FISH analysis was performed in certain cases on peripheral blood, BM aspirate and/or lymph node using DNA probe sets designed to detect common abnormalities associated with CLL (11) . Flow cytometric analyses on peripheral blood or BM aspirate specimens were performed on the FACSCalibur (BD Biosciences, San Jose, CA) and data were processed using CellQuest or CellQuest Pro software (BD Biosciences) as previously described(3).
We reviewed 288 patients identified in the database search for eligibility for inclusion in this study. Fifty-nine patients were excluded from the analysis because they were never evaluated in the in the Division of Hematology at MCR (n = 20), had inadequate clinical records (n = 15), review of the diagnosis showed that they had MCL (n = 13) or that flow cytometry was characteristic for CLL (n = 9) or was only performed on pleural fluid with a specimen that was not considered adequate for morphologic evaluation (n = 2) (Figure 1) . Two hundred and twenty nine patients were eligible for inclusion in the study. The results of analyses on this study cohort were compared to data obtained from the MCR CLL Database on 2,876 CLL patients seen at least once in the Division of Hematology at MCR during the same time period. This comparison was done to determine if the distinction between patients with CD5+B-CLPD and typical CLL has clinical implications for prognostication and management.
Statistical methods
To compare differences in characteristics between CD5+B-CLPD and CLL patients, χ 2 or Fisher's exact tests were used for qualitative variables, and non-parametric Kruskal-Wallis tests were used for quantitative variables. Descriptive statistics were calculated for variables collected in the CD5+B-CLPD dataset only. Survival and time to treatment analyses were performed with results displayed using Kaplan-Meier curves and p-values calculated using a log-rank test. Additionally, Cox proportional hazards analyses were conducted to adjust for age at onset. All statistical tests were two-sided and considered significant at the alpha = 0.05 level. All analyses were performed using SAS 9.1.
Results
The clinical characteristics of the 229 CD5+B-CLPD patients and 2,876 CLL comparison cohort are summarized in Table 1 . Compared to patients with CLL, those with CD5+B-CLPD were older at diagnosis with a lower proportion of males, lower percentage of palpable lymphadenopathy, higher percentage of palpable splenomegaly, and lower median ALC and hemoglobin at diagnosis. Although an equivalent percentage of CD5+B-CLPD patients required treatment (47% vs. 48%, p=0.82), CD5+B-CLPD patients were treated sooner after diagnosis than CLL patients (median 3.6 vs. 5.4 years, p=0.004) (Figure 2A ). Among the patients receiving their first treatment for CD5+B-CLPD (n = 104), the most common therapy was rituximab, either as monotherapy or in combination with high-dose steroids (34%), followed by alkylating agent (31%) or purine analog-containing combination regimens (15%), single agent alkylator therapy (14%), or other therapies (6%). In contrast, among the patients with CLL that required treatment (n = 1364), the most commonly used therapies were alkylating agents, either as monotherapy (32%) or in combination regimens (22%), and purine analog-based chemotherapy (32%), while single agent monoclonal antibody therapy (9%) and therapies with other drugs (5%) were less common.
Median follow-up from diagnosis was 2.4 years (range 0 to 25.1 years) for the CD5+B-CLPD patients and 6.2 years (range 0 to 45.9 years) for CLL patients. As of last follow-up, 65 (28%) CD5+B-CLPD patients and 1180 (41%) CLL patients had died. Age adjusted survival was significantly shorter in CD5+B-CLPD patients compared to CLL patients (median 8.4 years vs. 11.8 years, p=0.001) ( Figure 2B ).
Histopathological diagnosis
Seventy five (33%) CD5+B-CLPD patients subsequently underwent non-BM tissue biopsy (lymph node, n = 39; spleen, n = 21; mesentery, n = 2; bowel, n = 1; mediastinal mass, n = 2; lacrimal gland, n = 2; salivary gland, n = 1; epiglottis, n = 1; liver, n = 1; prostate gland, n = 2; pleura, n = 1; skin, n = 2). Of these, 61 (81%) samples were adequate for a comprehensive histopathological analysis and a definitive pathological diagnosis was ultimately possible in all these patients (Table 2)(10). Fourteen patients had tissue specimens that were inadequate for a definitive diagnosis; most were obtained as needle biopsies or were small crushed biopsy specimens. Because there was insufficient tissue for diagnostic evaluation in these 14 specimens, the diagnoses were generically considered to be CD5+B-CLPD, not otherwise specified (Figure 1) . Among the 61 patients with adequate tissue for a pathological examination, the most common diagnosis was CLL (n = 27, 44%). Thirty four patients had the leukemic phase of a known lymphoma: MZL (n = 21, 34%), LPL (n = 7, 11%), diffuse large B cell lymphoma (DLBCL)(n = 5, 8%), and high grade B cell lymphoma not otherwise specified (n = 1, 2%).
One hundred and two (44%) CD5+B-CLPD patients had at least one adequate BM aspiration and biopsy performed during the course of the study but did not have a non-BM tissue biopsy. Review of the BM and peripheral blood studies provided a definitive pathological diagnosis in only 24 (24%) subjects (Table 2) . Among these patients the most common diagnosis was LPL (n = 20, 83%). The two patients with HCL had an unusual phenotypic variant of this disease, expressing partial CD5, dim surface Ig, and bright CD20. The diagnosis was based on BM morphology with positive tartrate-resistant acid phosphatase (TRAP) staining of the malignant lymphocytes.
Fifty two patients (23%) had a diagnosis of CD5+B-CLPD based on peripheral blood studies alone. In these patients, no definitive diagnoses could be made on review of the available material and data. These patients, together with the 78 patients with non diagnostic BM studies and the 14 patients with an inadequate non-BM tissue biopsy were categorized as unclassified CD5+B-CLPD (n = 144) (Figure 1 ).
Unclassified CD5+B-CLPD
We further studied the patients with unclassified CD5+B-CLPD because this cohort is an important clinical entity in medical practice. For comparisons with the CLL cohort, we excluded 41 patients who met the diagnostic criteria for monoclonal B cell lymphocytosis (MBL) defined as an absolute lymphocyte count (ALC) < 5×10 9 /L and no palpable lymphadenopathy or organomegaly on physical examination (12) . An additional 3 patients were excluded because there was insufficient data to determine if they had MBL. ALC rather than B-lymphocyte count was used because, during this study, B-lymphocyte counts were not routinely used for the diagnosis of CLL(13) and were not available for most patients in our study. In this cohort of 100 unclassified CD5+B-CLPD, which represents a population of patients who are usually managed in a manner similar to CLL patients, we wished to determine if there were any substantive clinical characteristics that would warrant a different management approach.
The characteristics of the 100 non-MBL unclassified CD5+B-CLPD patients were compared to the 2,876 patients of the CLL cohort (Table 3) . CD5+B-CLPD patients were significantly older at diagnosis than CLL patients and 58% were symptomatic at presentation with weight loss (12%), drenching night sweats (10%), profound fatigue (23%), abdominal pain/ organomegaly (17%), bleeding or bruising (12%), recurrent infections (7%), and peripheral neuropathy (19%). CD5+B-CLPD patients were also more likely to have splenomegaly and cytopenia at diagnosis. Serum protein electrophoresis was performed in 57 of the CD5+ B-CLPD patients and a monoclonal protein was detected in the serum in 17 (30%) patients with a median concentration of 1.0 g/dL (range 0.1-5.9). The isotype was IgM in 6 and IgG in 11 patients and the serum light chain type was kappa in 65%.
A lower proportion of unclassified CD5+B-CLPD patients received treatment compared to the CLL cohort (34% vs. 48%, p=0.008). The most common treatment in the CD5+B-CLPD group was rituximab alone or in combination with high-dose corticosteroids (45%), alkylating agents, either as monotherapy (12%) or combination therapy (21%), purine analog-based regimens (15%), or other chemotherapeutic agents (7%). The time to treatment was longer for unclassified CD5+B-CLPD than for CLL patients (median 9.0 vs. 5.4 years) but this difference was not statistically significant (p=0.49) (Figure 2A ). Median follow-up from diagnosis was 1.9 years (range 0 to 25.1 years) for the unclassified CD5+B-CLPD patients and 6.2 years (range 0 to 45.9 years) for CLL patients. As of last follow-up, 23 (23%) unclassified CD5+ B-CLPD patients and 1180 (41%) CLL patients had died. Although survival was significantly shorter for the unclassified CD5+B-CLPD patients compared to the CLL patients (median 8.9 vs. 11.8 years, p = 0.02), there was no difference in the age-adjusted survival (p=0.15) ( Figure 2B ).
Discussion
Characterization of B-CLPD by immunophenotyping of cell membrane proteins has become an important and widely used diagnostic method in hematology. Because of the widespread availability of flow cytometry and an increased understanding of the immunophenotype of malignant B lymphocytes, most patients with B-CLPD can now be diagnosed by flow cytometric analysis of peripheral blood lymphocytes. However, a definitive diagnosis cannot be made in all patients with B-CLPD by these methods.
Flow cytometry scoring and pattern recognition recommendations have been developed to diagnose CLL and distinguish CLL from other lymphoproliferative disorders (2, 14, 15) . A previous study from our institution identified immunophenotypic patterns that could be used to guide interpretation of peripheral blood and bone marrow flow cytometric studies(3). These interpretations were based not on arbitrary "positivity" and "negativity" for particular antigens but incorporated intensity of surface immunoglobulin and CD20 staining and review of the histograms with CD5 and CD23 to assess whether the entire population or only a subset of the population expressed those antigens. Using these strict criteria, this previous study identified immunophenotypic patterns that were highly specific for CLL and had reasonable sensitivity. However, it is clear from these studies as well as from practical experience that there will be immunophenotypic overlap between the B-CLPD that express CD5 and that immunophenotypic analysis of blood and marrow alone cannot be used to accurately diagnose all B-CLPD. In patients with CD5+ B-cell clones that do not fulfill the criteria for the diagnosis of CLL, testing for the CCND1/IGH fusion gene generated by t(11;14) with FISH or for immunohistochemical expression of cyclin D1, will identify patients with the leukemic phase of MCL (8) . Patients with CD5+ B-cell clones that do not have the characteristic features of CLL or MCL, have frequently been considered to have "atypical CLL" (16) (17) (18) . The clinical utility of this designation is controversial and could imply that these patients have a unique disease, are CLL patients with an atypical immunophenotype, or have the leukemic phase of defined lymphomas.
A previous study suggested that patients with CD5+ B-cell clones who did not fulfill the Royal Marsden Criteria for diagnosis of CLL (14) could not be further classified using the available cytomorphological and immunophenotypic methods, and concluded that these patients could have a unique disease entity (6) . In contrast, in our study we were able to make a definitive diagnosis of a defined lymphoid malignancy based on World Health Organization criteria(4) in all CD5+B-CLPD patients in whom an adequate non-BM biopsy was available for examination (10) . Despite the atypical immunophenotype of circulating or BM derived lymphocytes, CLL was diagnosed in 44% of these patients with an adequate non-BM tissue biopsy. This finding suggests that CD5+B-CLPD is unlikely to include a new disease category and thus refutes our initial hypothesis. Of note, BM histology was only useful in providing a definitive diagnosis in a minority (24%) of CD5+B-CLPD patients. Our findings show that an accurate diagnosis of the underlying lymphoid malignancy in patients with CD5+B-CLPD requires surgical biopsy of a lymph node or other involved non-BM tissue.
CD5 expression in B-CLPD is not specific for CLL or MCL and has been reported to occur in 5 to 10% of LPL and 20% or more of MZL (3, 19, 20) . In this study we confirm that the most common definitive histological diagnosis in the CD5+B-CLPD cohort was CLL, with lower frequencies of MZL and LPL and only rare cases of DLBCL and HCL. In contrast, previous studies have shown that a definitive diagnosis of CLL is unlikely in patients with CD5-B-CLPD (5, 6, 21) . The most useful role of CD5+ expression in B-CLPD lacking the typical immunophenotypic characteristics of CLL, or the genetic defect of MCL, is to distinguish between patients with a higher (CD5+) or lower (CD5−) likelihood of having a histological diagnosis of CLL.
Our finding that CD5+B-CLPD is a biologically heterogeneous group of B cell neoplasms has important clinical implications. In this study we have shown that, although patients with unclassified CD5+B-CLPD can present with clinical features distinct from CLL, the percentage requiring treatment for progressive disease and the age adjusted survival are similar to CLL. Patients with CD5+B-CLPD and no indication for treatment can thus be monitored for disease progression. In contrast, optimal treatment for patients does require a specific diagnosis and we therefore recommend that all unclassified CD5+ B-CLPD patients undergo a non-BM tissue biopsy before initiation of therapy. Time to treatment (A) and overall survival (B) for CD5+B-CLPD patients and unclassified (non-MBL) CD5+ B-CLPD patients compared to CLL patients. Statistically significant differences exist between CD5+ B-CLPD patients and CLL patients for age-adjusted time to treatment (p=0.004) and age-adjusted survival (p<0.001), but the differences do not exist between unclassified (non-MBL) CD5+ B-CLPD patients and CLL patients (time to treatment p=0.49; age-adjusted survival p=0.15) All values are no. (%) unless otherwise indicated * Not available for assessment for 7 CD5+B-CLPD patients and 14 CLL patients ± Not available for assessment for 11 CD5+B-CLPD patients and 14 CLL patients § Not available for assessment for 19 CD5+B-CLPD patients and 14 CLL patients ¶ Defined as Hb < 11 g/dL, platelet count < 100 × 10 9 /L, or ANC < 1. 5 × 10 9 /L + Described according to published hierarchical criteria (23) .
